Table 1.
Baseline patient characteristics and adverse events (CTCAE any grade).
| Characteristics | Regorafenib | TAS | |
|---|---|---|---|
| n = 69 | n = 50 | ||
| Age at first diagnosis (years) | |||
| Median (Range) | 60 (33–81) | 59 (33–80) | |
| Sex (%) | |||
| Male | 49 (71) | 34 (68) | |
| Female | 20 (29) | 16 (32) | |
| Localization (%) | |||
| Right Colon | 15 (22) | 11 (22) | |
| Left Colon + Rectum | 54 (78) | 39 (78) | |
| Ras Gen Status (%) | |||
| Wildtyp | 36 (52) | 25 (50) | |
| Mutant | 33 (48) | 25 (50) | |
| BRAF Status (%) | |||
| Wildtyp | 63 (91) | 44 (88) | |
| Mutant | 1 (1) | 1 (2) | |
| Unknown | 5 (7) | 5 (10) | |
| Starting Dose/day (%) | |||
| 80 mg | 35 mg/m2 | 2 (3) | 50 (100) |
| 120 mg | 21 (30) | ||
| 160 mg | 46 (67) | ||
| Therapyline (%) | |||
| Regorafenib only | 35 (51) | ||
| Regorafenib before TAS | 32 (46) | 32 (64) | |
| TAS before regorafenib | 2 (3) | 2 (4) | |
| TAS only | 16 (32) | ||
| Adverse events (%) | |||
| Fatigue | 29 (42.0) | 26 (52.0) | |
| Hand-Foot-Skin-Reaction | 25 (36.2) | 0 (0) | |
| Hoarseness | 24 (34,8) | 0 (0) | |
| Weightloss/Anorexia | 21 (30.4) | 8 (16) | |
| Hypertension | 14 (20.3) | 0 (0) | |
| Nausea/Vertigo | 14 (20.3) | 17 (34) | |
| Diarrhea | 13 (18.8) | 12 (24) | |
| Oral-Mucositis/Stomatitis | 11 (15.9) | 0 (0) | |
| Abdominal Pain | 8 (11.6) | 7 (14) | |
| Absence of appetite | 8 (11.6) | 0 (0) | |
| Paraesthesis/Neuropathie | 6 (8.7) | 0 (0) | |
| Anaemia | 0 (0) | 13 (26) | |
| Neutropenia | 0 (0) | 10 (20) | |
| Leukopenia | 0 (0) | 11 (22) | |
| Vomiting | 0 (0) | 9 (18) | |